CTMX
CytomX Therapeutics Inc
2.70$
-1.1%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 626.4% | -355.5% | -13.5% | 237.9% | -126.9% | -244.4% | 7.7% | -171.1% | -208.4% | -55.4% | -62.4% | -99.2% | |
| 15.4% | 15.6% | 11.5% | 2.3% | 3.2% | 4.5% | 3.8% | 3.9% | 4.6% | 2.1% | 1.3% | 1.8% | |
| 10.9% | 51.7% | 67.1% | 15.8% | 28.4% | 33.2% | 21.6% | 18.9% | 24.7% | 8.5% | 5.6% | 8.3% | |
| 12.1% | 89.7% | 78.9% | 30.5% | 28.4% | 36.0% | 21.6% | 18.9% | 24.8% | – | – | – | |
| 1,195.1% | -3.2% | 287.6% | 265.2% | -13.4% | -54.6% | 26.5% | -78.6% | -57.7% | -61.8% | -91.5% | -90.0% | |
| 32.8% | 20.7% | 14.5% | 2.2% | 6.4% | 6.1% | 3.4% | 2.3% | 3.3% | 0.8% | 0.2% | 0.3% | |
| -32.8% | -1,693.0% | 304.9% | -169.3% | 10.0% | 138.6% | -27.4% | 32.3% | 184.8% | -148.9% | 72.2% | -78.4% | |
| – | 86.9% | 0.0% | 0.0% | – | – | – | – | – | – | – | 3.9% | |
| 0.2% | 86.9% | 6.2% | 33.2% | 234.7% | 2.8% | 24.7% | 158.4% | 207.3% | – | – | – | |
| -24.7% | -39.8% | 0.5% | – | – | – | – | – | – | – | – | – | |
| 503.3% | 1,989.1% | 6.6% | 33.2% | 234.7% | 2.8% | 24.7% | 158.4% | 1.2% | 29.9% | 5.4% | 144.9% | |
| 1,097.0% | -59.3% | 298.0% | 101.8% | 117.7% | -102.9% | 5.0% | 19.6% | -22.3% | -174.4% | 15.2% | -32.7% | |
| 593.6% | -376.2% | -28.0% | 235.7% | -133.3% | -250.4% | 4.3% | -173.4% | -211.7% | -56.2% | -62.7% | -99.5% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.